Abstract

Naproxen 25 mg/mL in SyrSpend SF pH4

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2022 - Volume 26, Number 2

Page(s): 145

Download in electronic PDF format for $75
  • Naproxen 25 mg/mL in SyrSpend SF pH4 Page 1

Abstract

A formulation for preparing Naproxen 25 mg/mL in SyrSpend SF pH4. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • naproxen
  • nonsteroidal anti-inflammatory agent
  • NSAID
  • inflammation
  • analgesia
  • analgesic
  • pain control
  • fever
  • migraine headache
  • antipyrogenic agent
  • oral suspension

Related Categories

  • EXCIPIENTS
  • FORMULATIONS
  • PAIN MANAGEMENT
  • DOSAGE FORMS/DRUG CARRIERS
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2022
Pg. 145
Naproxen 25 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 54
Naproxen 25 mg/mL in Oral Mix or Oral Mix SF
Author(s): Allen Loyd V Jr
May/Jun 2014
Pg. 239
Naproxen 25-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Sep/Oct 2016
Pg. 410
Naproxen 5% Cream
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 53
Ketoprofen 20-mg/mL in SyrSPend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2004
Pg. 101-105
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Jan/Feb 2021
Pg. 46
Diclofenac Sodium 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Nov/Dec 1999
Pg. 496-500
Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations
Author(s): Goodwin Donald A, Fuhram L Clifton
Sep/Oct 2017
Pg. 409
Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2016
Pg. 155-158
Utilization of Compounded Medications in an Oral Medicine Practice
Author(s): Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Jul/Aug 2014
Pg. 278-286
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2012
Pg. 270-274
A Concise Discussion of Headache Types, Part 3: Migraine
Author(s): Williams LaVonn A, Allen Loyd V Jr
Mar/Apr 2024
Pg. 100-109
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2016
Pg. 233
Pain-Away II Headache Capsules
Author(s): Allen Loyd V Jr
Jan/Feb 2020
Pg. 60
Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 42
Acetaminophen (Paracetamol) 50 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 315
Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr